Literature DB >> 34364982

Post-translational down-regulation of Nrf2 and YAP proteins, by targeting deubiquitinases, reduces growth and chemoresistance in pancreatic cancer cells.

Margherita Grattarola1, Marie Angèle Cucci1, Antonella Roetto1, Chiara Dianzani2, Giuseppina Barrera1, Stefania Pizzimenti3.   

Abstract

The intrinsic chemoresistance of pancreatic ductal adenocarcinoma (PDAC) represents the main obstacle in treating this aggressive malignancy. It has been observed that high antioxidant levels and upregulated Nrf2 and the YAP protein expression can be involved in PDAC chemoresistance. The mechanisms of Nrf2 and YAP increase need to be clarified. We chose a panel of PDAC cell lines with diverse sensitivity to cisplatin and gemcitabine. In PANC-1 chemoresistant cells, we found a low level of oxidative stress and high levels of Nrf2 and YAP protein expressions and their respective targets. On the contrary, in CFPAC-1 chemosensitive cells, we found high levels of oxidative stress and low level of these two proteins, as well as their respective targets. In MiaPaCa-2 cells with a middle chemoresistance, we observed intermediate features. When Nrf2 and YAP were inhibited in PANC-1 cells by Ailanthone, a plant extract, we observed a reduction of viability, thus sustaining the role of these two proteins in maintaining the PDAC chemoresistance. We then delved into the mechanisms of the Nrf2 and YAP protein upregulation in chemoresistance, discovering that it was at a post-translational level since the mRNA expressions did not match the protein levels. Treatments of PANC-1 cells with the proteasome inhibitor MG-132 and the protein synthesis inhibitor cycloheximide further confirmed this observation. The expression of DUB3 and OTUD1 deubiquitinases, involved in the control of Nrf2 and YAP protein level, respectively, was also investigated. Both protein expressions were higher in PANC-1 cells, intermediate in MiaPaCa-2 cells, and lower in CFPAC-1 cells. When DUB3 or OTUD1 were silenced, both Nrf2 and YAP expressions were downregulated. Importantly, in deubiquitinase-silenced cells, we observed a great reduction of proliferation and a higher sensitivity to gemcitabine treatment, suggesting that DUB3 and OTUD1 can represent a suitable target to overcome chemoresistance in PDAC cells.
Copyright © 2021. Published by Elsevier Inc.

Entities:  

Keywords:  Chemoresistance; Deubiquitinases; Nrf2; Oxidative stress; PDAC cells; YAP

Year:  2021        PMID: 34364982     DOI: 10.1016/j.freeradbiomed.2021.08.006

Source DB:  PubMed          Journal:  Free Radic Biol Med        ISSN: 0891-5849            Impact factor:   7.376


  5 in total

1.  The deubiquitinase OTUD1 inhibits non-small cell lung cancer progression by deubiquitinating and stabilizing KLF4.

Authors:  Xiaoyan Ma; Liming Wang; Guifang Shi; Shuqing Sun
Journal:  Thorac Cancer       Date:  2022-01-30       Impact factor: 3.500

Review 2.  Deubiquitinases in Cancers: Aspects of Proliferation, Metastasis, and Apoptosis.

Authors:  Jiaqi Liu; Chi Tim Leung; Luyun Liang; Yuqin Wang; Jian Chen; Keng Po Lai; William Ka Fai Tse
Journal:  Cancers (Basel)       Date:  2022-07-21       Impact factor: 6.575

3.  Deubiquitylase OTUD1 confers Erlotinib sensitivity in non-small cell lung cancer through inhibition of nuclear translocation of YAP1.

Authors:  Huafeng Liu; Liting Zhong; Yanjun Lu; Xuewen Liu; Jiawang Wei; Yuhai Ding; Huiling Huang; Qihong Nie; Xiaohong Liao
Journal:  Cell Death Discov       Date:  2022-10-01

Review 4.  Oxidative Stress-Related Mechanisms in Melanoma and in the Acquired Resistance to Targeted Therapies.

Authors:  Stefania Pizzimenti; Simone Ribero; Marie Angele Cucci; Margherita Grattarola; Chiara Monge; Chiara Dianzani; Giuseppina Barrera; Giuliana Muzio
Journal:  Antioxidants (Basel)       Date:  2021-12-03

Review 5.  Role of Nrf2 in Pancreatic Cancer.

Authors:  Marta Cykowiak; Violetta Krajka-Kuźniak
Journal:  Antioxidants (Basel)       Date:  2021-12-30
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.